MedPath

Regadenoson

Generic Name
Regadenoson
Brand Names
Lexiscan, Rapiscan
Drug Type
Small Molecule
Chemical Formula
C15H18N8O5
CAS Number
313348-27-5
Unique Ingredient Identifier
7AXV542LZ4
Background

Regadenoson is an A2A adenosine receptor agonist that causes coronary vasodilation and used for myocardial perfusion imagining. Manufactured by Astellas and FDA approved April 10, 2008.

Indication

Diagnostic agent for radionuclide myocardial perfusion imaging (MPI)

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET

Phase 2
Recruiting
Conditions
Sickle Cell Disease
Interventions
Drug: [13N]NH3
Drug: Lexiscan
Diagnostic Test: Positron emission tomography
First Posted Date
2022-10-18
Last Posted Date
2024-10-11
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
40
Registration Number
NCT05583721
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Treat COVID-19 Patients With Regadenoson

Phase 1
Completed
Conditions
COVID-19
Lung Inflammation
Interventions
Other: Placebo Control
Drug: Regadenoson
First Posted Date
2020-10-28
Last Posted Date
2023-08-15
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
5
Registration Number
NCT04606069
Locations
🇺🇸

University of Maryland Medical Center, Baltimore, Maryland, United States

A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients

Phase 1
Recruiting
Conditions
Myocardial Ischemia
Coronary Artery Disease
Interventions
Drug: Regadenoson
First Posted Date
2020-10-27
Last Posted Date
2024-12-02
Lead Sponsor
GE Healthcare
Target Recruit Count
54
Registration Number
NCT04604782
Locations
🇬🇷

Mitera Hospital, Athens, Greece

🇫🇷

Paris Public Hospitals System; Necker Hospital for Sick Children, Paris, France

🇮🇹

Bambino Gesu Children Hospital, Roma, Italy

and more 2 locations

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

Early Phase 1
Conditions
MRI Scans
Interventions
Drug: Adenosine
Drug: Regadenoson
Drug: O-15 labeled radioactive water
Device: MRI
Device: PET Imaging
First Posted Date
2020-10-23
Last Posted Date
2020-10-23
Lead Sponsor
University of Utah
Target Recruit Count
100
Registration Number
NCT04600115
Locations
🇺🇸

university of Utah, Radiology Research, Salt Lake City, Utah, United States

Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

Early Phase 1
Completed
Conditions
Lung Transplant
Interventions
Drug: Placebo
Drug: Regadenoson
First Posted Date
2020-08-20
Last Posted Date
2024-08-05
Lead Sponsor
University of Maryland, Baltimore
Target Recruit Count
47
Registration Number
NCT04521569
Locations
🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

University of Maryland Medical Center, Baltimore, Maryland, United States

The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

Not Applicable
Recruiting
Conditions
Coronary Artery Disease
Interventions
Diagnostic Test: PET-MPI Protocol
Diagnostic Test: CT-MPI
Diagnostic Test: CT-FFR
Drug: Regadenoson
First Posted Date
2020-03-20
Last Posted Date
2024-04-15
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT04316676
Locations
🇺🇸

Emory University Hospital, Atlanta, Georgia, United States

Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer

Completed
Conditions
Anatomic Stage IB Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Premenopausal
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Interventions
Biological: Adenosine
Procedure: Magnetic Resonance Imaging
Drug: Regadenoson
Procedure: Stress Management Therapy
First Posted Date
2018-04-23
Last Posted Date
2020-03-26
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
25
Registration Number
NCT03505736
Locations
🇺🇸

Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve

Phase 4
Terminated
Conditions
Hypertrophic Cardiomyopathy
Microvascular Ischaemia of Myocardium
Non-ischemic Dilated Cardiomyopathy
Interventions
Drug: Regadenoson
Drug: Adenosine
First Posted Date
2017-08-15
Last Posted Date
2020-09-16
Lead Sponsor
Duke University
Target Recruit Count
31
Registration Number
NCT03249272
Locations
🇺🇸

Duke Cardiovascular Magnetic Resonance Center, Durham, North Carolina, United States

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Phase 2
Terminated
Conditions
Microvascular Coronary Artery Disease
Interventions
Drug: Placebo
Drug: SAR407899
Drug: Adenosine
Drug: Regadenoson
Drug: 13N-ammonia
Drug: 82Rubidium
First Posted Date
2017-08-01
Last Posted Date
2022-03-24
Lead Sponsor
Sanofi
Target Recruit Count
10
Registration Number
NCT03236311
Locations
🇺🇸

Investigational Site Number 8400001, Jacksonville, Florida, United States

🇺🇸

Investigational Site Number 8400013, Wellington, Florida, United States

🇩🇰

Investigational Site Number 2080001, København Nv, Denmark

and more 7 locations

Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT

Completed
Conditions
Coronary Artery Disease
Interventions
Diagnostic Test: Cardiac Perfusion Rest/Stress Digital PET/CT
Drug: N-13 ammonia
Drug: Regadenoson
First Posted Date
2017-05-31
Last Posted Date
2021-10-26
Lead Sponsor
Stanford University
Target Recruit Count
15
Registration Number
NCT03170817
Locations
🇺🇸

Stanford University, Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy